Lung Cancer Market To Surpass USD 67.9 Billion By 2030 At A CAGR Of 14.1%
The report analyzes and forecasts the Lung Cancer Market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2022 to 2030. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Lung Cancer Market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Lung Cancer Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Lung Cancer Market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Download Sample Report Copy From Here:https://www.acumenresearchandconsulting.com/request-sample/2708
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding. Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
Market Players as below:
Some of the top lung cancer market companies offered in the professional report includes AstraZeneca plc, Eli Lilly and Company, The Merck Group, Sanofi S.A., Pfizer Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, and Boehringer Ingelheim GmbH.
The major market segments of Lung Cancer Market are as below:
Lung Cancer Market By Type
- SCLC
- NSCLC
Lung Cancer Market By Treatment
- Surgery
- Chemotherapy
- Photodynamic Therapy (PDT)
- Radiotherapy
- Laser Therapy
Lung Cancer Market By End-User
- Hospitals & Clinics
- Cancer Research Centers
- Laboratories
Ask Query Here: richard@acumenresearchandconsulting.com or sales@acumenresearchandconsulting.com
Table Of Contents:
CHAPTER 1. Industry Overview of Lung Cancer Market
1.1. Definition and Scope
1.1.1. Definition of Lung Cancer
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Lung Cancer Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Lung Cancer Market By Type
1.2.3. Lung Cancer Market By Treatment
1.2.4. Lung Cancer Market By End-User
1.2.5. Lung Cancer Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data End-User
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Lung Cancer Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Lung Cancer Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Lung Cancer Market By Type
4.1. Introduction
4.2. Lung Cancer Revenue By Type
4.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By Type, 2018-2030
4.2.2. SCLC
4.2.2.1. SCLC Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
4.2.3. NSCLC
4.2.3.1. NSCLC Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 5. Lung Cancer Market By Treatment
5.1. Introduction
5.2. Lung Cancer Revenue By Treatment
5.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By Treatment, 2018-2030
5.2.2. Surgery
5.2.2.1. Surgery Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Chemotherapy
5.2.3.1. Chemotherapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Photodynamic Therapy (PDT)
5.2.4.1. Photodynamic Therapy (PDT) Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.5. Radiotherapy
5.2.5.1. Radiotherapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.6. Laser Therapy
5.2.6.1. Laser Therapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. Lung Cancer Market By End-User
6.1. Introduction
6.2. Lung Cancer Revenue By End-User
6.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By End-User, 2018-2030
6.2.2. Hospitals & Clinics
6.2.2.1. Hospitals & Clinics Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.3. Cancer Research Centers
6.2.3.1. Cancer Research Centers Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.4. Laboratories
6.2.4.1. Laboratories Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 7. North America Lung Cancer Market By Country
7.1. North America Lung Cancer Market Overview
7.2. U.S.
7.2.1. U.S. Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
7.2.2. U.S. Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
7.2.3. U.S. Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.3. Canada
7.3.1. Canada Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
7.3.2. Canada Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
7.3.3. Canada Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.4. North America PEST Analysis
CHAPTER 8. Europe Lung Cancer Market By Country
8.1. Europe Lung Cancer Market Overview
8.2. U.K.
8.2.1. U.K. Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
8.2.2. U.K. Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
8.2.3. U.K. Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.3. Germany
8.3.1. Germany Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
8.3.2. Germany Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
8.3.3. Germany Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.4. France
8.4.1. France Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
8.4.2. France Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
8.4.3. France Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.5. Spain
8.5.1. Spain Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
8.5.2. Spain Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
8.5.3. Spain Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.6. Rest of Europe
8.6.1. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
8.6.2. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
8.6.3. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Lung Cancer Market By Country
9.1. Asia Pacific Lung Cancer Market Overview
9.2. China
9.2.1. China Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.2.2. China Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.2.3. China Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.3. Japan
9.3.1. Japan Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.3.2. Japan Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.3.3. Japan Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.4. India
9.4.1. India Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.4.2. India Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.4.3. India Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.5. Australia
9.5.1. Australia Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.5.2. Australia Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.5.3. Australia Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.6. South Korea
9.6.1. South Korea Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.6.2. South Korea Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.6.3. South Korea Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
9.7.2. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
9.7.3. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Lung Cancer Market By Country
10.1. Latin America Lung Cancer Market Overview
10.2. Brazil
10.2.1. Brazil Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
10.2.2. Brazil Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
10.2.3. Brazil Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.3. Mexico
10.3.1. Mexico Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
10.3.2. Mexico Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
10.3.3. Mexico Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.4. Rest of Latin America
10.4.1. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
10.4.2. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
10.4.3. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Lung Cancer Market By Country
11.1. Middle East & Africa Lung Cancer Market Overview
11.2. GCC
11.2.1. GCC Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
11.2.2. GCC Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
11.2.3. GCC Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.3. South Africa
11.3.1. South Africa Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
11.3.2. South Africa Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
11.3.3. South Africa Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030
11.4.2. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030
11.4.3. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Lung Cancer Market
12.1. Lung Cancer Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Lung Cancer Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. AstraZeneca plc
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Billion), 2021
13.1.3.2. AstraZeneca plc 2021 Lung Cancer Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Eli Lilly and Company
13.3. The Merck Group
13.4. Sanofi S.A.
13.5. Pfizer Inc.
13.6. GlaxoSmithKline
13.7. F. Hoffmann-La Roche AG
13.8. Boehringer Ingelheim GmbH
To Get Premium Report Full Copy in Form of Single user or Multiple user@https://www.acumenresearchandconsulting.com/buy-now/0/2708
About Us:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
